An Act to amend and reenact §§ 3.2-4113, 4.1-1604, 18.2-36.3, 18.2-250, 18.2-251, 18.2-251.03 through 18.2-251.1:3, 18.2-308.1:5, 19.2-327.15, 32.1-45.4, and 54.1-3466 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 18.2-250.01, relating to possession of residue of a controlled substance; penalties; exceptions.
HB637 makes a broad set of changes to Virginia law focused on controlled substances, drug residue, fentanyl-related offenses, and related exceptions for lawful hemp and cannabis activities. The bill adds a new offense, possession of residue of a controlled substance, and then threads that offense into multiple existing statutes so that it is treated similarly to other drug-possession crimes for purposes of probation, immunity exceptions, firearm restrictions, trafficking-related definitions, and other criminal provisions. It also updates several laws to clarify that certain people and entities involved in industrial hemp, cannabis oil, pharmaceutical processing, laboratories, and state agriculture/law enforcement duties are not subject to prosecution when acting within authorized duties.
The bill also revises the involuntary manslaughter statute to specifically address deaths caused by controlled substances containing fentanyl, making it a felony when a person knowingly manufactures, sells, or distributes such a substance and another person dies as a result. In addition, it amends the Commonwealth’s harm-reduction framework by clarifying that possession of controlled paraphernalia does not apply to certain naloxone-related uses, comprehensive harm reduction programs, and related needle/syringe distribution. The measure also makes conforming changes to statutes involving first-offense drug probation, overdose and sexual-violence immunity, cannabis oil in schools and care facilities, and human-trafficking record relief definitions.
In practical terms, HB637 expands criminal liability for drug residue while also creating or preserving exceptions for lawful hemp, cannabis, naloxone, and harm-reduction activities. It affects defendants charged with drug offenses, law-enforcement and prosecutors, hemp growers and processors, cannabis processors and dispensaries, health-care and long-term-care workers, laboratories, and agencies such as the Department of Agriculture and Consumer Services and the Department of Law. The bill also affects firearm eligibility rules tied to repeated misdemeanor drug convictions and the availability of certain post-conviction relief provisions.
The overall sentiment reflected in the bill’s final status is mixed but ultimately favorable enough to pass the legislature, though it did not become law because the House sustained the Governor’s veto. The structure of the bill suggests a policy compromise: it is tough on fentanyl and drug-residue enforcement while simultaneously protecting legitimate hemp, cannabis, and harm-reduction operations from unintended prosecution. That combination indicates support for both public-safety enforcement and regulated medical or agricultural uses.
The main points of contention are likely the new residue offense and the fentanyl-related involuntary manslaughter expansion, which increase criminal exposure for drug-related conduct, versus the carve-outs for lawful hemp, cannabis oil, and harm-reduction programs. Opponents may have viewed the bill as overbroad or duplicative, especially where it extends drug penalties into many other code sections, while supporters likely emphasized closing loopholes, addressing overdose deaths, and clarifying lawful exceptions. The veto and subsequent House action suggest the bill remained politically contested even after passage.
HB637 amends a wide range of Virginia Code provisions governing drug crimes, hemp, cannabis, overdose immunity, paraphernalia, firearm disabilities, trafficking-related relief, and harm-reduction programs. Its most significant legal change is the creation of § 18.2-250.01, establishing possession of residue of a controlled substance as a punishable offense and integrating that offense into existing criminal and collateral-consequence statutes. It also narrows or clarifies exceptions for industrial hemp, cannabis oil, naloxone, and authorized public-health or laboratory activities, while expanding fentanyl-related involuntary manslaughter liability and updating related probation and firearm-disqualification rules.
The bill appears to have had a generally supportive but divided reception: it advanced through the legislative process and was approved, but the Governor vetoed it and the House later sustained that veto. The text reflects a policy approach that combines stricter drug enforcement, especially around fentanyl and residue possession, with explicit protections for lawful hemp, cannabis, medical, and harm-reduction activities. That blend suggests the bill was seen by supporters as a targeted public-safety measure, while critics likely objected to its punitive reach or complexity.
The most notable contention centers on whether creating a separate offense for controlled-substance residue and expanding fentanyl-related manslaughter liability is an appropriate enforcement response or an overextension of criminal law. Another likely point of dispute is the bill’s many cross-references and exceptions, which may have raised concerns about complexity, unintended consequences, or inconsistent treatment of people handling hemp, cannabis oil, naloxone, or paraphernalia in lawful settings. Supporters of harm reduction and regulated cannabis/hemp industries would favor the explicit exemptions, while tougher-on-crime advocates would focus on the new penalties and collateral consequences.